BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32108043)

  • 21. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.
    Haddad BR; Erickson A; Udhane V; LaViolette PS; Rone JD; Kallajoki MA; See WA; Rannikko A; Mirtti T; Nevalainen MT
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1642-1651. PubMed ID: 31292140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
    Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
    Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer.
    Lage-Vickers S; Bizzotto J; Valacco MP; Sanchis P; Nemirovsky S; Labanca E; Scorticati C; Mazza O; Mitrofanova A; Navone N; Vazquez E; Cotignola J; Gueron G
    Commun Biol; 2021 Jan; 4(1):103. PubMed ID: 33483585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
    Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer.
    Li X; Wan X; Chen H; Yang S; Liu Y; Mo W; Meng D; Du W; Huang Y; Wu H; Wang J; Li T; Li Y
    Clin Cancer Res; 2014 May; 20(9):2312-25. PubMed ID: 24610824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.
    Léon P; Cancel-Tassin G; Drouin S; Audouin M; Varinot J; Comperat E; Cathelineau X; Rozet F; Vaessens C; Stone S; Reid J; Sangale Z; Korman P; Rouprêt M; Fromond-Hankard G; Cussenot O
    World J Urol; 2018 Sep; 36(9):1495-1500. PubMed ID: 29679140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of serum response factor expression in prostate cancer biochemical recurrence.
    Prencipe M; Fabre A; Murphy TB; Vargyas E; O'Neill A; Bjartell A; Tasken KA; Grytli HH; Svindland A; Berge V; Eri LM; Gallagher W; Watson RW
    Prostate; 2018 Jul; 78(10):724-730. PubMed ID: 29608018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.
    Chen L; Lei Z; Ma X; Huang Q; Zhang X; Zhang Y; Hao P; Yang M; Zhao X; Chen J; Liu G; Zheng T
    Sci Rep; 2016 Sep; 6():33604. PubMed ID: 27640814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.
    Trinh VQ; Benzerdjeb N; Chagnon-Monarque S; Dionne N; Delouya G; Kougioumoutzakis A; Sirois J; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Zorn KC; Fradet Y; Saad F; Taussky D; Trudel D
    Radiat Oncol; 2019 Apr; 14(1):60. PubMed ID: 31018850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
    Xu S; Yi XM; Zhang ZY; Ge JP; Zhou WQ
    Mol Med Rep; 2016 Dec; 14(6):5025-5032. PubMed ID: 27779679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.
    Walz J; Joniau S; Chun FK; Isbarn H; Jeldres C; Yossepowitch O; Chao-Yu H; Klein EA; Scardino PT; Reuther A; Poppel HV; Graefen M; Huland H; Karakiewicz PI
    BJU Int; 2011 Mar; 107(5):765-770. PubMed ID: 20875089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.
    Cattarino S; Seisen T; Drouin SJ; Renard-Penna R; Leon P; Comperat E; Mozer P; Cussenot O; Rouprêt M
    Can J Urol; 2015 Apr; 22(2):7703-8. PubMed ID: 25891333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
    Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
    BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
    Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
    BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of positive surgical margins after radical prostatectomy among pT2 and pT3a prostate cancer.
    Oh JJ; Hong SK; Byun SS; Choe G; Lee SE
    Urol Oncol; 2013 Jul; 31(5):595-600. PubMed ID: 21658977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
    Gu C; Li Q; Zhu Y; Qu Y; Zhang G; Wang M; Yang Y; Wang J; Jin L; Wei Q; Ye D
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):310-6. PubMed ID: 26238235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.